Quarterly ResultAug 12, 2026, 05:19 PM
Nexalin Faces Nasdaq Delisting, Going Concern Doubt Amid Losses
AI Summary
Nexalin Technology reported a net loss of $(4.34) million and significantly decreased revenue of $27,111 for the six months ended June 30, 2026. The company received a Staff Delisting Determination from Nasdaq due to non-compliance with the minimum bid price requirement and management expressed substantial doubt about its ability to continue as a going concern. Despite these financial challenges, Nexalin acquired PONM, Inc. to expand its technology portfolio and initiated a clinical trial for its Gen-3 HALO device for insomnia.
Key Highlights
- Nasdaq issued Staff Delisting Determination; company requested hearing to appeal.
- Management raised substantial doubt about the company's ability to continue as a going concern.
- Reported a net loss of $(4.34) million for the six months ended June 30, 2026.
- Revenue decreased to $27,111 for the six months ended June 30, 2026.
- Cash used in operating activities was $(3.51) million for the six-month period.
- Acquired PONM, Inc. for approximately $1.3 million in common stock.
- Initiated FDA-cleared clinical trial for Gen-3 HALO device for insomnia.
Price Impact
More from NXL